Effect of long-term administration of progestogen on post-menopausal bone loss: result of a two-year, controlled randomized study
Article first published online: 17 MAR 2008
Volume 38, Issue 6, pages 627–631, June 1993
How to Cite
Trémollières, F., Pouilles, J. M. and Ribot, C. (1993), Effect of long-term administration of progestogen on post-menopausal bone loss: result of a two-year, controlled randomized study. Clinical Endocrinology, 38: 627–631. doi: 10.1111/j.1365-2265.1993.tb02145.x
- Issue published online: 17 MAR 2008
- Article first published online: 17 MAR 2008
- (Received 10 July 1992; returned for revision 24 November 1992; finally revised 7 December 1992; accepted 75 January 1993)
OBJECTIVE We determined whether a progestogen given alone to post-menopausal women may prevent bone loss.
STUDY DESIGN Thirty-five early post-menopausal women who had not received any form of treatment to prevent bone loss were randomly assigned to a 2-year regimen of 500 μ g/day of a gestagen derived from 19-norprogester-one (Promegestone) or a placebo for 21 days out of a 28-day treatment cycle. Bone mineral density of the spine was measured by dual photon absorptiometry.
RESULTS After 2 years of treatment bone mineral density decreased significantly in the placebo group by a mean of 4.5%. In the gestagen group, the rate of bone change was significantly lower as compared to the placebo group (-1.3%± 1.2% vs −4.5%± 2% (mean ± SEM), P & lt; 0.05). There were no changes in the biochemical bone turnover parameters in the placebo group but in the gestagen group a significant decrease was observed in the urinary calcium excretion after 2 years.
CONCLUSION The results suggest that a gestagen with no androgenic action can partly counteract early post-menopausal bone loss.